Clinical trials: Reflux
Gastroesophageal Reflux Disease (GERD)
Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
The study is designed to test the safety and efficacy of the Medigus SRS endoscopic stapling system for the treatment of GERD. The system allows the operator to staple the stomach to the esophagus,in order to restore the…
- Trial name
- NCT00734747
- Testing
- Medigus SRS endoscopic stapling system
- Where
- 6 sites in United States, Austria and 3 more
- Volunteers
- 72 people
- Sponsor
- Aviel Roy-Shapira, M.D.
Symptomatic Gastroesophageal Reflux Disease (sGERD)
Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)
The purpose of this study is to compare the efficacy, safety and tolerability of rabeprazole extended release (ER) 50 mg with placebo in subjects with symptomatic gastroesophageal reflux disease (sGERD).
- Trial name
- NCT00911534
- Testing
- rabeprazole sodium
- Where
- 98 sites in United States
- Volunteers
- 305 people
- Sponsor
- Eisai Inc.
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
The primary aim of this study was to determine the proportion of patients with esophageal eosinophilic infiltration that have objective (measurable) evidence of gastroesophageal reflux disease (GERD).
- Conditions
- Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
- Trial name
- NCT00728481
- Testing
- Esomeprazole, Budesonide
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Mayo Clinic
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to determine the safety and efficacy of Rabeprazole extended release (ER) 50 mg versus Esomeprazole 40 mg for healing and symptomatic relief among subjects with erosive gastroesophageal reflux disease…
- Trial name
- NCT00658528
- Testing
- Rabeprazole sodium, Esomeprazole
- Where
- 88 sites in United States, Argentina and 11 more
- Volunteers
- 1,061 people
- Sponsor
- Eisai Inc.
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive…
- Trial name
- NCT00658775
- Testing
- Rabeprazole sodium, Esomeprazole
- Where
- 83 sites in United States, Argentina and 12 more
- Volunteers
- 1,069 people
- Sponsor
- Eisai Inc.
Gastroesophageal Reflux Disease
Narrow-band Imaging, Autofluorescence Imaging and Gastroesophageal Reflux Disease
Aim of this study is to compare the efficacy of narrow band imaging (NBI) and autofluorescence imaging (AFI) to distinguish subtle mucosal change related to acid reflux that is not visible in standard white light imaging (WLI)…
- Trial name
- NCT01504971
- Testing
- symptom questionaire, pH monitoring, Tri-modal imaging endoscopy
- Where
- China
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca
Venous Insufficiency, Venous Reflux
Effects of Non Contact Low Frequency Ultrasound in Healing Venous Leg Ulcers
This trial is a prospective, randomized, controlled, multi-center study of subjects presenting with chronic lower extremity venous ulcers.
- Conditions
- Venous Insufficiency, Venous Reflux, Lower Extremity Ulcer
- Trial name
- NCT01549860
- Testing
- MIST Therapy
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- Celleration, Inc.
Gastroparesis, Gastroesophageal Reflux
Domperidone for Gastroparesis in Solid Organ Transplantation
The purpose of this study is to examine the clinical response to domperidone in solid organ transplant recipients with gastroparesis.
- Trial name
- NCT00552422
- Testing
- domperidone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- David J. Lederer, M.D.
Laryngopharyngeal Reflux
Treatment of Extraesophageal Reflux With the Reza Band UES Assist Device
The purpose of the study is to determine the safety and effectiveness of non-invasive Reza Band UES Assist Device for the treatment of esophagopharyngeal reflux with extra-esophageal symptoms (chronic cough, choking, aspiration…
- Trial name
- NCT01857713
- Testing
- Reza Band UES Assist Device
- Where
- 5 sites in United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Somna Therapeutics, L.L.C.
Gastroesophageal Reflux Disease, Erosive Esophagitis
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
The purpose of this study is to assess the safety and effectiveness of treatment with once daily oral administration of dexlansoprazole delayed-release capsules in adolescents with erosive esophagitis (EE) and for maintenance of…
- Trial name
- NCT01642615
- Testing
- Dexlansoprazole
- Where
- 60 sites in United States, Belgium and 6 more
- Volunteers
- 63 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease, Functional Bowel Disorders
Temple Registry for the Investigation of African American Gastrointestinal Disease Epidemiology
DESCRIPTION: Minimal data exists on the prevalence of gastroesophageal reflux disease in minority populations. Specific objectives of this K24 research project are to: (1) Provide an estimate of the prevalence of gastroesophageal…
- Trial name
- TRIAGE (NCT01262755)
- Testing
- Structured Interview
- Where
- United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Temple University
Gastroesophageal Reflux Disease
Clinical Studies on Bile Acids in Barrett's Esophagus
This study has two major goals: 1. To determine the effects of bile salts on causing DNA injury and activating signaling pathways that promote growth in cells from the esophagus of patients who have gastroesophageal reflux…
- Trial name
- NCT00858858
- Testing
- Ursodeoxycholic Acid
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- US Department of Veterans Affairs
Gastro-esophageal Reflux
Safety Study of Airway Clearance Techniques in Infants.
The purpose of this study is to determine whether three airway clearance techniques ( Bouncing, Assisted Autogenic Drainage ( AAD) and bouncing and AAD) provoke or aggravate gastro-esophageal reflux in infants under the age of 1…
- Trial name
- NCT02128867
- Testing
- Assisted Autogenic Drainage (AAD), bouncing and AAD, bouncing
- Where
- Belgium
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Vrije Universiteit Brussel
Gastroesophageal Reflux Disease, Erosive Esophagitis
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
The purpose of this study is to measure the in-vivo disintegration time of a single dexlansoprazole delayed-release orally disintegrating (OD) tablet.
- Conditions
- Gastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn
- Trial name
- NCT02096458
- Testing
- Dexlansoprazole
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Takeda
Gastroesophageal Reflux Disease
Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US
The purpose of this research study is to compare the safety and effectiveness (how well the medicine works) of esomeprazole (study drug) to placebo (a capsule that does not contain any medication) taken daily in relieving…
- Trial name
- NCT00660660
- Testing
- Esomeprazole
- Where
- 45 sites in United States
- Volunteers
- 276 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI
The purpose of this project is to compare the efficacy (how successful) 1) standard-dose proton pump inhibitor (PPI) (rabeprazole 20 mg once daily) (a medication that completely blocks the stomach from producing acid) plus low…
- Trial name
- NCT00539240
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- US Department of Veterans Affairs
Gastroesophageal Reflux Disease
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
The purpose of this study was to assess the safety and effectiveness of once daily oral administration of dexlansoprazole delayed-release capsules in adolescent participants with symptomatic non-erosive gastroesophageal reflux…
- Trial name
- NCT01642602
- Testing
- Dexlansoprazole
- Where
- 64 sites in United States, Belgium and 6 more
- Volunteers
- 104 people
- Sponsor
- Takeda
Asthma, GERD
Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma
The purpose of this study is to determine whether treatment with esomeprazole for 6 months will improve asthma in adult patients with moderate to severe asthma and symptoms of gastroesophageal reflux disease.
- Trial name
- RELAX (NCT00317044)
- Testing
- Esomeprazole
- Where
- 130 sites in United States, Argentina and 12 more
- Volunteers
- 961 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD)
Phase 3/Safety & Efficacy of Esomeprazole in Infants
The purpose of this study is to look at the improvement of a once a day dose of esomeprazole for reducing the signs and symptoms of infants with gastroesophageal reflux disease (GERD).
- Trial name
- NCT00468559
- Testing
- Open Label Run In Esomeprazole, Double Blind Esomeprazole
- Where
- 25 sites in United States, France and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca